DOI: 10.7759/cureus.46587

Review began 10/01/2023 Review ended 10/04/2023 Published 10/06/2023

© Copyright 2023

Alameer. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Surgicel® Granuloma Mimicking Recurrent Thyroid Tumor After Thyroidectomy: A Case Report and Literature Review

Ehab Alameer 1

1. Department of Surgery, College of Medicine, Jazan University, Jazan, SAU

Corresponding author: Ehab Alameer, esalameer@jazanu.edu.sa

Abstract

Oxidized regenerated cellulose, commonly known by the brand name Surgicel®, is a hemostatic agent widely used in various surgical procedures. While it is generally considered safe and effective, there have been reports of complications associated with its use, including the formation of pseudotumoral lesions. This article presents a case of a patient who developed a Surgicel® granuloma in the thyroid bed, mimicking a recurrent tumor. Surgicel® is known to cause a chronic inflammatory reaction, leading to foreign body giant cell formation and fibroblastic proliferation. Fine-needle aspiration (FNA) cytology is a valuable diagnostic tool for identifying pseudotumoral lesions caused by oxidized cellulose. The characteristic appearance of oxidized cellulose fragments and the presence of a granulomatous reaction can help distinguish these lesions from tumor recurrence or abscesses. To prevent Surgicel® granuloma, it is recommended to use the minimal amount necessary to achieve hemostasis. It is also important to document its use in the operative report. In cases where a recurrent mass lesion is suspected postoperatively, a comprehensive medical history, imaging studies, and FNA are essential for accurate diagnosis and management. This case report highlights the importance of considering Surgicel®-induced granuloma in the differential diagnosis of recurrent thyroid-bed tumors. A correct diagnosis can help avoid unnecessary aggressive interventions, particularly in cancer patients.

Categories: Otolaryngology, Pathology, General Surgery

 $\textbf{Keywords:} \ thyroid \ surgery, surgicel \\ @ \ granuloma, \ recurrent \ tumor, \ pseudotumoral \ lesion, \ postoperative, oxidized \ regenerated \ cellulose$

Introduction

Hemostasis is a crucial aspect of thyroid surgery, and various topical hemostatic agents are commonly employed as supplements to conventional methods of hemostasis (such as suture ligation, clips, electrocautery, and energy devices). These agents have gained widespread acceptance for use in both open and minimally invasive surgeries due to their ease of application [1-3]. In thyroid surgery, a commonly utilized absorbable collagen sheet hemostat is Surgicel®. This product provides a scaffold for clot formation and is thought to be efficacious in managing minor bleeding [4]. Although its effectiveness may be a subject of debate, the use of oxidized cellulose in neck or thyroid surgery is generally considered safe [5,6]. The application of hemostatic patches offers several advantages, including reduced operative time, drain output, and hospital stay after thyroid surgery [5].


However, the utilization of oxidized regenerated cellulose as a hemostatic agent has been linked to complications such as foreign body reactions and granuloma formation [7-9], which can occur months or even years after surgery [10]. The exact mechanism behind the development of these granulomas is not well understood. Several case reports [7-17] have described the presence of oxidized cellulose-induced granulomas in various anatomical locations, including the gastrointestinal tract, ovaries, mediastinum, liver, brain, kidney, and nasal cavity.

In this report, we present a case of a symptomatic neck mass that recurred two years after thyroid lobectomy, which was found to be a Surgicel® granuloma.

Case Presentation

A 42-year-old female patient was referred to the endocrine surgery clinic with a suspicious nodule in the right thyroid lobe. She had previously undergone two non-diagnostic fine-needle aspirations (FNAs). After discussing all options, the patient opted for a right thyroid lobectomy and isthmusectomy. The procedure and recovery were uneventful. The pathological evaluation of the surgical specimen revealed thyroid tissue exhibiting follicular adenoma, which was encapsulated and composed of variable-sized follicles lined by flattened to cuboidal epithelial cells with variable amounts of colloid. There was no evidence of capsular or vascular invasion. The rest of the thyroid tissue contained nodules separated by fibrovascular septa, which showed variable-sized follicles lined by cuboidal to flattened epithelial cells, and contained variable amounts of colloid. No atypia or malignancy was present.

Two years after the initial presentation, the patient returned with a visible anterior neck mass underlying the well-healed surgical scar, which was causing "disfigurement and a feeling of pressure in the neck." Ultrasound (Figure 1) revealed that the right thyroid lobe had been surgically removed, but an elongated, well-defined isoechoic lesion measuring $2.5\times1.5\times0.8$ cm was present in the operative bed. The lesion showed no calcifications. The left lobe was unremarkable. An FNA of the lesion showed striated muscle fibers, a few macrophages, and degenerated debris, but no epithelial cells were identified.








FIGURE 1: Ultrasound of the pre-tracheal lesion showing an elongated, well-defined isoechoic lesion measuring 2.5 x 1.5 x 0.8 cm in the operative bed

The lesion showed no calcifications

After a thorough discussion with the patient, taking into account the symptomatic nature of the mass, the diagnostic uncertainty, and the high level of anxiety, and despite the benign pathology reported following the prior thyroidectomy, we decided to proceed with surgical excision. The tumor was primarily located in the pre-tracheal area, with adhesive extensions into the right tracheoesophageal groove, and was completely removed (Figure 2). The surgery and recovery were unremarkable. The final pathology report revealed chronic xanthogranulomatous inflammation with a foreign body reaction and the presence of foreign material. There were foamy macrophages and a foreign body reaction with multinucleated giant cells surrounding the foreign material, indicative of a granuloma. No atypia or evidence of malignancy was observed, and no lymph node or caseous necrosis was found.



FIGURE 2: The removed pre-tracheal tumor

Upon reviewing the operative note from the initial surgery, it was confirmed that Surgicel® was used for hemostasis at the conclusion of the surgery.

Discussion

The application of hemostatic substances during surgical procedures has become a widespread practice. Among these substances, oxidized cellulose is commonly used due to its biocompatibility, bactericidal properties, and absorption characteristics [18,19]. Surgicel®, a type of oxidized regenerated cellulose, typically dissolves within two to six weeks and has a pH-lowering effect on its surroundings, which may increase inflammation in the surrounding tissue [18]. Surgicel®'s acidic properties cause red blood cells to break down, leading to a change in color when it comes into contact with blood. This change is the result of hemoglobin reacting with acid to form acid hematin [18].

The low pH also exhibits antimicrobial properties and functions as a caustic agent, facilitating blood clotting by creating an artificial clot [18]. However, the acidic environment generated by oxidized cellulose may inactivate other biologically active topical agents, such as thrombin, limiting its ability to be used in combination with other treatments. Furthermore, Surgicel®'s acidic nature may exacerbate inflammation in surrounding tissue and hinder the wound healing process [20].

The duration of oxidized cellulose dissolution depends on the amount used, with a range of two to six weeks. However, there are cases where histological evidence of oxidized cellulose fibers has been observed several

years after cardiac surgery [21-23]. Additionally, there have been reports of Surgicel® migrating through the intervertebral foramen and causing spinal cord compression after thoracotomy [24,25].

Besides thyroidectomy, the use of absorbable hemostatic agents, such as Surgicel®, has been investigated in other neck surgeries. For example, one study [26] compared the use of Suturation plus Surgicel® application in managing post-tonsillectomy bleeding and pain. The study found that while the combination of Suturation and Surgicel® reduced the incidence of bleeding, it resulted in increased pain levels compared to other treatment approaches.

Browder and Litwin [27] investigated the effectiveness of Surgicel® in controlling bleeding in general surgical patients, including at the cut surface of the thyroid gland. Their study found that Surgicel® was effective in achieving hemostasis and did not result in any foreign body reactions, infections, or allergic manifestations.

The effectiveness of oxidized regenerated cellulose-based products, such as Surgicel®, in preventing post-surgical adhesion formation has also been investigated in several studies. While some research has indicated that Surgicel® may prevent adhesions, other studies have found inconclusive evidence [28].

In one study, an absorbable collagen-based adhesive was found to reduce adhesions following liver injury in rats [29]. Another study compared the effectiveness of a collagen-based adhesive and conventional absorbable sutures in treating hepatic injury in rats. The adhesive group had shorter hemostasis times and a lower incidence of adhesions [30].

There have been some complications associated with the use of Surgicel® in thyroid surgery. Although studies have demonstrated no significant difference in the incidence of postoperative hypocalcemia when using Surgicel® [6], there have been instances of pseudotumoral lesions induced by oxidized cellulose hemostatic agents.

Notably, Surgicel® granulomas have been documented in various surgical procedures beyond thyroid surgery, including abdominal surgery, neurosurgery, gynecological surgery, and urological surgery [7-17]. These granulomas can exhibit imaging characteristics that resemble recurrent tumors or abscesses, necessitating further examination or resection to differentiate between a foreign-body reaction and tumor recurrence.

In experimental studies using animal models, it has been shown that oxidized cellulose can cause a chronic inflammatory reaction leading to foreign body giant cell formation and fibroblastic proliferation [31].

Hernández-Bonilla et al. [9] described a series of pseudotumoral lesions induced by oxidized cellulose hemostatic agents, including Surgicel®, which can result in a granulomatous reaction. FNA cytology was found to be helpful in detecting these pseudotumoral lesions and differentiating them from tumor recurrence. The authors emphasized the importance of pathologists being familiar with this finding.

The authors evaluated 16 patients who developed these lesions after surgical procedures where oxidized cellulose was used. FNA samples were obtained from various sites, including the mediastinum, thyroid surgical bed, axilla, neck, vulva, liver, and retroperitoneum. The time interval between surgery and FNA ranged from 4 to 46 months. The cytology samples consistently showed foreign-body material with a variable granulomatous reaction. Oxidized cellulose appeared as laminated inorganic fragments with an elongated quadrangular appearance. Additional features included amorphous, ill-defined fragments and a dense proteinaceous background with phagocytic cells.

FNA cytology is a valuable diagnostic tool for identifying pseudotumoral lesions caused by hemostatic agents such as oxidized cellulose. The consistent presence of foreign-body material with a granulomatous reaction and the characteristic appearance of oxidized cellulose fragments can help distinguish these lesions from tumor recurrence or abscesses.

It is essential for physicians to be familiar with the clinical presentation, diagnostic approach, prevention, and management of Surgicel® granuloma. Management often involves excision due to the presence of symptoms or diagnostic uncertainty. To prevent Surgicel® granuloma, it is recommended to use the minimal amount of Surgicel® necessary to achieve hemostasis. Additionally, it is important to note the use of hemostatic agents in the operative report.

This case report adds to the growing body of literature highlighting the importance of considering oxidized cellulose-induced granuloma in the differential diagnosis when evaluating patients with recurrent mass lesions postoperatively.

Conclusions

In conclusion, Surgicel® granuloma is a possible cause of recurrent thyroid-bed tumors. To accurately

diagnose and manage this condition, a comprehensive medical history, imaging studies, and FNA are crucial. This is particularly important in cancer patients, as a correct diagnosis can help avoid unnecessary aggressive interventions.

Additional Information

Author Contributions

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.

Concept and design: Ehab Alameer

Acquisition, analysis, or interpretation of data: Ehab Alameer

Drafting of the manuscript: Ehab Alameer

Critical review of the manuscript for important intellectual content: Ehab Alameer

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

- Lewis KM, Li Q, Jones DS, et al.: Development and validation of an intraoperative bleeding severity scale for use in clinical studies of hemostatic agents. Surgery. 2017, 161:771-81. 10.1016/j.surg.2016.09.022
- Eden C, Buonomo OC, Busch J, et al.: An international multidisciplinary peer-driven consensus on the optimal use of hemostatic powders in surgical practice. Updates Surg. 2021, 73:1267-73. 10.1007/s13304-021-01136-x
- O'Hanlan KA, Bassett P: Exploring adverse events and utilization of topical hemostatic agents in surgery . ISLS. 2022. 26:e2022.00033. 10.4293/ISLS.2022.00033
- $4. \quad Signorelli\ F, Montano\ N:\ Use\ and\ efficacy\ of\ hemostats\ in\ neurosurgery\ .\ Surg\ Technol\ Int.\ 2020,\ 37:414-9.$
- 5. Khadra H, Bakeer M, Hauch A, Hu T, Kandil E: Hemostatic agent use in thyroid surgery: a meta-analysis . Gland Surg. 2018, 7:S34-41. 10.21037/gs.2018.03.02
- 6. Del Rio P, Cataldo S, Pisani P, De Simone B, Iapichino G, Sianesi M: Use of oxidized and regenerated cellulose in thyroid surgery: a prospective analysis as cause of postoperative hypocalcemia on 485 patients consecutively treated. Minerva Endocrinol. 2011, 36:157-62.
- 7. Lemoy MJ, Schouten AC, Canfield DR: Granuloma due to oxidized regenerated cellulose in an aged rhesus macaque (Macaca mulatta). Comp Med. 2016, 66:59-62.
- 8. Ribalta T, McCutcheon IE, Neto AG, et al.: Textiloma (gossypiboma) mimicking recurrent intracranial tumor. Arch Pathol Lab Med. 2004, 128:749-58. 10.5858/2004-128-749-TGMRIT
- Hernández-Bonilla S, Rodríguez-García AM, Jiménez-Heffernan JA, et al.: FNA cytology of postoperative pseudotumoral lesions induced by oxidized cellulose hemostatic agents. Cancer Cytopathol. 2019, 127:765-70. 10.1002/cncy.22194
- Loh RT, Matys T, Allinson KS, Santarius T: Intracranial gossypiboma 9 years after intracranial pressure bolt insertion: illustrative case. J Neurosurg Case Lessons. 2022, 3:10.3171/CASE21479
- 11. Wang H, Chen P: Surgicel® (oxidized regenerated cellulose) granuloma mimicking local recurrent gastrointestinal stromal tumor: a case report. Oncol Lett. 2013, 5:1497-500. 10.3892/ol.2013.1218
- 12. Gao HW, Lin CK, Yu CP, Yu MS, Chen A: Oxidized cellulose (Surgicel) granuloma mimicking a primary ovarian tumor. Int J Gynecol Pathol. 2002, 21:422-3. 10.1097/00004347-200210000-00015
- Tefik T, Sanli O, Oktar T, Yucel OB, Ozluk Y, Kilicaslan I: Oxidized regenerated cellulose granuloma mimicking recurrent mass lesion after laparoscopic nephron sparing surgery. Int J Surg Case Rep. 2012, 3:227-30. 10.1016/j.ijscr.2012.03.001
- Cormio L, Cormio G, Di Fino G, Scavone C, Sanguedolce F, Loizzi V, Carrieri G: Surgicel(®) granuloma mimicking ovarian cancer: a case report. Oncol Lett. 2016, 12:1083-4. 10.3892/ol.2016.4689
- Haidari TA, Petersen RH, Skov BG, Ravn J: Oxidized resorbable cellulose (Gelita-cel) causing foreign body reaction in the mediastinum. Interact Cardiovasc Thorac Surg. 2018, 27:881-3. 10.1093/icvts/ivy180
- Al-Afif S, Hatipoglu Majernik G, Hermann EJ, Esmaeilzadeh M, Hartmann C, Krauss JK: Intracranial foreign material granulomas after cranial surgery. Acta Neurochir (Wien). 2018, 160:2069-75. 10.1007/s00701-018-3663-0
- Ganau M, Nicassio N, Tacconi L: Postoperative aseptic intracranial granuloma: the possible influence of fluid hemostatics. Case Rep Surg. 2012, 2012:614321. 10.1155/2012/614321
- Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH: A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg. 2010, 251:217-28. 10.1097/SLA.0b013e3181c3bcca

- Franceschini G: Internal surgical use of biodegradable carbohydrate polymers. Warning for a conscious and proper use of oxidized regenerated cellulose. Carbohydr Polym. 2019, 216:213-6. 10.1016/j.carbpol.2019.04.036
- 20. Tomizawa Y: Clinical benefits and risk analysis of topical hemostats: a review . J Artif Organs. 2005, 8:137-42. 10.1007/s10047-005-0296-x
- Ibrahim MF, Aps C, Young CP: A foreign body reaction to Surgicel mimicking an abscess following cardiac surgery. Eur J Cardiothorac Surg. 2002, 22:489-90; author reply 490. 10.1016/s1010-7940(02)00328-7
- 22. Tomizawa Y, Endo M, Kitamura M, Shiikawa A, Yagi Y, Koyanagi H: Coronary artery bypass graft stenosis suspected to be due to hemostatic agents: a case report. Kyobu Geka. 1991, 44:764-6.
- 23. Igari T, Iwaya F, Abe T, et al.: A case of foreign body granuloma after aortic valve replacement . Kyobu Geka. 1990, 43:550-2.
- Banerjee T, Goldschmidt K: 'Surgiceloma' manifested as cauda equina syndrome. South Med J. 1998, 91:481-3. 10.1097/00007611-199805000-00016
- Brodbelt AR, Miles JB, Foy PM, Broome JC: Intraspinal oxidised cellulose (Surgicel) causing delayed paraplegia after thoracotomy--a report of three cases. Ann R Coll Surg Engl. 2002, 84:97-9.
- Cetiner H, Cavusoglu I, Duzer S, Sakallioglu O, Susaman N, Yildirim YS: Effect of Suturation plus Surgicel application on post-tonsillectomy bleeding and pain. J Craniofac Surg. 2017, 28:e672-5. 10.1097/SCS.000000000003827
- Browder IW, Litwin MS: Use of absorbable collagen for hemostasis in general surgical patients. Am Surg. 1986, 52:492-4.
- Chicone G, de Carvalho VF, Paggiaro AO: Use of oxidized regenerated cellulose/collagen matrix in chronic diabetic foot ulcers: a systematic review. Adv Skin Wound Care. 2018, 31:66-71.
 10.1097/01.ASW.0000527297.95688.76
- Oliveira FM, Carvalho MV, Marchi E, Pinto CA: Collagen, fibrinogen and thrombin biological addesive is effective in treating experimental liver injuries. Rev Col Bras Cir. 2016, 43:254-61. 10.1590/0100-69912016004004
- Singh A, Jai S, Ganpule S, Ganpule A: Bolster material granuloma masquerading as recurrent renal cell carcinoma following partial nephrectomy. Indian J Radiol Imaging. 2016, 26:352-5. 10.4103/0971-3026.190418
- Kim SH, Yoon HS, In CH, Kim KS: Efficacy evaluation of SurgiGuard® in partially hepatectomized pigs.
 Korean J Hepatobiliary Pancreat Surg. 2016, 20:102-9. 10.14701/kjhbps.2016.20.3.102